CorEvitas Generalized Pustular Psoriasis Registry

The National Psoriasis Foundation is supporting a CorEvitas independent clinical registry in generalized pustular psoriasis (GPP), with the PPD™ clinical research business of Thermo Fisher Scientific. The GPP registry is collecting real-world patient data over time. The registry addresses an unmet need for clinical and patient-reported outcomes for patients living with GPP.

 
A black male nurse holds a clipboard and talks to a woman patient.
Icon illustration of a question mark in a chat bubble.

What is GPP?

With generalized pustular psoriasis (GPP), pustules often cover large areas of the body and typically present with fever, shivers, intense itching, a rapid pulse, fatigue, headache, nausea, muscle weakness, and joint pain. GPP is a rare disease that affects approximately one of every 10,000 people in the United States. Untreated flares can be accompanied by severe complications that, if left untreated, can be life-threatening.

An icon of a group of three people.

Who can participate?

The registry is enrolling patients with a diagnosis of GPP, who are at least 18 years of age, and are willing to provide a limited set of health data. Individuals do not need to be on any specific treatment or be actively flaring to be enrolled. Because of the rarity of the disease, each person is critically important to the registry.

icon image of papers

What information is collected?

Dermatology providers will collect data during each routine clinic visit or when patients have a flare. Clinician-reported outcomes include clinical assessments for GPP, lab measures, and treatment history. Patient-reported outcomes assess symptom impact and quality of life. Drug safety data will be collected, including serious adverse events and other events of special interest.

An icon of a target with an arrow in the center.

What is the impact?

The GPP registry will help create new information and knowledge about GPP, including data to improve understanding of the disease, treatment patterns and effectiveness, and the safety and efficacy of new treatments coming to market.

Learn More About the Registry

Patients

If you are living with GPP and interested in participating in this registry, talk to your dermatology provider and encourage them to reach out to NPF or CorEvitas to learn more.

Dermatologists

If you are interested in becoming a site for this registry, please contact CorEvitas. As a participating site in this groundbreaking registry, you are contributing to the knowledge base on GPP.

Questions?

Please reach out with any questions or if you are interested in participating in this program.

Get in touch

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


The National Psoriasis Foundation is a qualified 501(c)(3) EIN 93-0571472.


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.